US EditionClick, Boehringer DTx for Schizophrenia Passes Phase 3 Test
AMSTERDAM, THE NETHERLANDS, AUG 7 – CT-155 demonstrated significant reduction in negative symptoms of schizophrenia as an adjunct to antipsychotic therapy in a 16-week phase 3 trial, addressing a major unmet need affecting 60% of patients.
- Boehringer Ingelheim and Click Therapeutics announced that CT-155, their investigational prescription digital therapeutic for schizophrenia, successfully achieved the main goal in the critical Phase III CONVOKE clinical trial.
- The CONVOKE trial investigated the effectiveness of CT-155, a mobile app-based intervention, used in combination with conventional antipsychotic medication, to reduce the negative symptoms experienced by individuals with schizophrenia, a disorder that affects roughly 24 million people worldwide.
- CT-155 is a mobile app providing interactive psychosocial techniques and showed a significant reduction in experiential negative symptoms over 16 weeks while maintaining a favorable safety profile.
- Shaheen Lakhan, Click’s chief medical and scientific officer, stated that the CONVOKE trial delivers initial phase 3 data demonstrating the promise of a prescribed digital therapeutic used alongside conventional antipsychotic treatment to address a fundamental aspect of schizophrenia.
- The positive results mark a critical advancement in addressing the unmet needs of people with negative schizophrenia symptoms and support regulatory breakthrough device designation granted earlier this year.
11 Articles
11 Articles
Globe Newswire
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured...
CT-155 Digital Therapeutic Meets Primary Endpoint in Phase III Trial for Negative Symptoms of Schizophrenia
An investigational prescription digital therapeutic, CT […] The post CT-155 Digital Therapeutic Meets Primary Endpoint in Phase III Trial for Negative Symptoms of Schizophrenia first appeared on GeneOnline News. The post CT-155 Digital Therapeutic Meets Primary Endpoint in Phase III Trial for Negative Symptoms of Schizophrenia appeared first on GeneOnline News.
Medical Device Network
Clinical Trials ArenaBoehringer and Click seek schizophrenia PDT approval after Phase III success
Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trialThe post Boehringer and Click seek schizophrenia PDT approval after Phase III success appeared first on Medical Device Network.
Investigational Prescription Digital Therapeutic CT-155 for Negative Symptoms of Schizophrenia Meets Primary Study Endpoint
Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
